REVELATION BIOSCIENCES, INC.

Revelation is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (AKI) and GEM-CKD as a treatment for chronic kidney disease (CKD). Revelation was incorporated in Delaware on November 20, 2019, originally as Petra Acquisition, Inc., and is based in San Diego, California. Its common stock and Public Warrants are listed on The Nasdaq Stock Market, LLC (Nasdaq) under the ticker symbols "REVB" and "REVBW," respectively. On June 23, 2025, stockholders granted discretionary authority to the board of directors to amend the certificate of incorporation for reverse stock splits. Following this, a 1-for-3 reverse stock split of outstanding common stock became effective on July 7, 2025. Additionally, a 1-for-4 reverse stock split of outstanding common stock became effective on January 28, 2026.